Aspen Pharmacare Holdings Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| APN.JO | 1795.TW | MOREPENLAB.BO | AARTIDRUGS.NS | INDSWFTLAB.NS | EMCURE.BO | |
|---|---|---|---|---|---|---|
| Market cap | 72.80B | 44.76B | 53.04B | 40.63B | 31.52B | 424.98B |
| P/E (TTM) | — | 11.8 | 54.1 | 21.3 | 37.0 | 38.9 |
| Forward P/E | 12.5 | 7.1 | — | 16.0 | — | 27.9 |
| Price/book | 0.9 | 1.9 | 4.4 | 2.4 | 2.1 | 8.0 |
| Dividend yield | 1.42% | 1.61% | 0.51% | 0.44% | — | 0.17% |
| 1-year change | +68.95% | −42.88% | −37.48% | −6.77% | +240.08% | +59.82% |
| Today | +2.69% | +5.66% | −3.44% | −2.34% | −3.72% | +3.02% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All APN.JO news ›South Africa's Aspen Pharmacare to sell women's health product in Europe to Ennogen
JOHANNESBURG, Nov 2 (Reuters) - South Africa's Aspen Pharmacare will sell the European commercialisation rights and related intellectual property for its women's health product Ovestin to Ennogen Healthcare International for €197 million…
From the 4Search news index, newest first.